u/tb500_tangent

Careful with that mean.

nhs_waitlist_n is right about the programme names. They are different populations with different endpoints.

Independent result added to the log — there are very few on that compound.

Disagree — that is a rodent study and you are stating it as a human effect. The distance between those is the entire argument.

Did they name the facility?

Agreed that thin testing here says something about the members, not about the material.

Same. Net peptide content is where the difference between the label and the vial actually shows up.

a mean is not a promise

On the thin testing history in this board, and what to do about it.

Most of the compounds discussed here have a handful of independent results across the entire site, and several have none. That is a fact about how few members have paid for testing, not a judgement about the material.

What follows: buy small, test identity first for anything unusual, and post the result even when it is unremarkable. The vendor source pages are built from exactly these submissions, and the compounds with the thinnest coverage are the ones where one more entry changes the picture most. Research material is not approved for human use, so what this board can usefully build is an analytical record.

Standing reminder: research-use-only material is not approved for human use, and no outcome claims without evidence.

What is the beyond-use date and what is it based on?

the API source is the question nobody asks and everybody should

Has anyone posted an independent result on that batch?

open-label extensions are not the same evidence as the randomised phase

Agreed. And the interval, not the point estimate, is what the trial actually established.

503A or 503B — do you know which?

Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.

read the actual papers, they are more modest than the summaries

Asked for a catalogue number rather than removing. Common names are ambiguous here and it makes threads unusable later.

Why purity and net content diverge, and why that is usually honest.

Purity by area percent is a relative measure of what the detector saw. Net peptide content subtracts counterion, water and residual solvent from the powder mass. For some compounds in this catalogue the gap between the two is large.

A vial can therefore be 99% pure and contain considerably less peptide by mass than the label weight suggests, with nothing wrong anywhere. The problem is not the chemistry; it is that people compare a purity figure from one supplier with a net content figure from another and conclude something about both. Ask which number you are being shown, every time.

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

Has anyone here tested that compound at all?

Yes — the rodent literature is real and it is rodent literature. The gap to a human claim is enormous and it gets crossed in one sentence here.

I would not extrapolate a mechanism from a model system to a person in one step, which is what that comment does.

if it matters, ask somebody qualified in your own jurisdiction

Adding the standing caveat — nothing here is legal advice and this one genuinely warrants somebody qualified.

Purity methods differ by compound class.

This is the rule for anything unusual. Identity before anything else.

do not post your own address details when asking

Independent result added to the log — there are very few on that compound.

How long was the randomised phase before any extension?

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.